4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor [EPC]

825 reported adverse events

Drugs of this class: NITISINONE

These side effects are most commonly reported by patients taking drugs of the 4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor [EPC] class:

# Side effect Count
0 AMINO ACID LEVEL INCREASED 133
1 LIVER TRANSPLANT 118
2 HEPATOCELLULAR CARCINOMA 61
3 ALPHA 1 FOETOPROTEIN INCREASED 52
4 TREATMENT NONCOMPLIANCE 51
5 OFF LABEL USE 48
6 CATARACT 47
7 HEPATIC FAILURE 45
8 DEATH 38
9 HEPATIC CIRRHOSIS 37
See all common reactions for 4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor [EPC]

Drugs of the 4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 SUCCINYLACETONE INCREASED 34 0.9444
1 TYROSINAEMIA 8 0.6667
2 AMINO ACID LEVEL INCREASED 133 0.1790
3 ACRODERMATITIS ENTEROPATHICA 2 0.0952
4 LENTICULAR OPACITIES 34 0.0778
5 ALPHA 1 FOETOPROTEIN INCREASED 52 0.0730
6 AMINO ACID LEVEL DECREASED 19 0.0564
7 ALPHA 1 FOETOPROTEIN DECREASED 2 0.0500
8 LIVER TRANSPLANT 118 0.0324
9 HEPATOBLASTOMA 3 0.0309
See all enriched reactions for 4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor [EPC]